Catabasis Pharmaceuticals (NASDAQ: CATB) this morning reported positive results in the MoveDMD trial across multiple functional assessments, which were recently presented at the American Academy of Neurology 69th Annual Meeting. Numerical improvements were seen in prespecified rate change analyses across five functional assessments in part B of the trial, which was designed to evaluate the potential of edasalonexent in the treatment of Duchenne muscular dystrophy (DMD). These results are consistent with the numerical improvements in the same functional assessments with edasalonexent compared to placebo after 12 weeks of edasalonexent treatment. Part C interim results are anticipated for the third quarter of 2017. “Coupled with the reassuring safety, tolerability and plasma exposure data in patients affected by Duchenne, we are optimistic about edasalonexent’s potential and look forward to continuing to evaluate it as a novel treatment for this devastating disease,” Catabasis chief medical officer Joanne Donovan, M.D., Ph.D., stated in the news release.
To view the full press release, visit: http://nnw.fm/5CWKp
Catabasis Pharmaceuticals is engaged in developing therapies using its SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform to engineer molecules that simultaneously modulate multiple targets in a disease. The company is applying its SMART linker platform to build an internal pipeline of product candidates for rare diseases and plans to pursue partnerships to develop additional product candidates. For more information on the company’s drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer